Elan Frovelan
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Launch of the migraine therapy frovatriptan is expected this year with a co-promotion partner, Elan says. Frovelan (formerly Miguard) has been "approvable" since April 2000. The firm says it has responded to all questions FDA had about Frovelan and ziconotide, which has been "approvable" since Decembe